Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
RGNX
#2557
REGENXBIO Inc.
9.040
0
+8.00%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+8.00%
Changement Mensuel
-5.88%
Evolution sur 6 mois
-32.69%
Changement Annuel
-32.69%
Clôture Précédente
8.370
0
Open
9.040
0
Bid
Ask
Low
9.040
0
High
9.040
0
Volume
78
Marchés
Actions des Marchés US
Soins de Santé
RGNX
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
42.5 M
42.95 M
43.46 M
44.43 M
50.09 M
—
Valuation ratios
Enterprise value
1.59 B
1.06 B
870.11 M
780.28 M
329.64 M
1.32 B
Price to earnings ratio
-15.22
11.24
-3.42
-3.05
-1.68
-9.2
Price to sales ratio
10.94
3.05
8.52
8.89
4.89
12.97
Price to cash flow ratio
31.28
6.56
4.63
3.67
2.21
14.07
Price to book ratio
4.48
1.88
1.86
2.57
1.47
2.72
Enterprise value to EBITDA ratio
41.99
3.3
-19.46
-13.65
-5.56
—
Profitability ratios
Return on assets %
0.16
0.11
0.34
0.46
0.49
0.36
Return on equity %
0.29
0.17
0.54
0.85
0.87
0.93
Return on invested capital %
226.49
126.79
177.57
257.21
402.58
—
Gross margin %
71.91
88.43
51.61
58.76
50.76
346.65
Operating margin %
77.14
34.01
233.2
297.12
297.91
728.3
EBITDA margin %
24.49
68.28
-39.67
-63.37
-75.71
—
Net margin %
71.98
27.18
248.68
291.99
289.94
788.25
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
6.52
3.98
3.19
2.57
2.69
11.42
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.26
0.52
0.12
0.13
0.15
0.32
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
1.45
4.98
4.81
4.99
3.5
2.03
EBIT per share
1.04
7.45
-0.93
-1.29
-1.11
—
EBITDA per share
1.02
7.31
-1.04
-1.31
-1.2
—
Total debt per share
—
—
—
—
—
—
Cash per share
14.02
19.34
13.1
7.18
4.95
23.15
Net current asset value per share
14.25
11.81
9.64
7.66
5.62
25.39
Tangible book value per share
10.13
17.4
11.96
7.13
5.24
17.85
Working capital per share
12.06
8.84
6.62
4.68
3.53
16.5
Book value per share
10.13
17.4
11.96
7.13
5.24
17.85
Nouvelles
FDA yorumları sonrası Stifel’den uniQure değerlendirmesi
Stifel comments on uniQure shares after FDA commissioner remarks
Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now? - TipRanks.com
REGENXBIO: Cautiously Bullish After FDA Setbacks (NASDAQ:RGNX)
Regenxbio stock price target lowered to $32 at H.C. Wainwright after FDA rejection
Intel, Wells Fargo among market cap stock movers on Tuesday
Netflix and Oracle among market cap stock movers on Tuesday
Regenxbio stock price target lowered by Goldman Sachs on RGX-121 setback
REGENXBIO hisseleri FDA’nın Hunter sendromu için gen tedavisini reddetmesinin ardından düştü
After-hours movers: ON Semiconductor, Credo, Upwork, Regenxbio, and more